Clasado Biosciences just released a video explainer featuring Dr Lucien Harthoorn, R&D Director, and Pieter Van den Abbeele, cofounder & CSO of Cryptobiotix, presenting the company’s latest research on Bimuno® GOS. The study demonstrates that just 380 mg of active GOS per day can significantly increase levels of beneficial Bifidobacterium species, including B. adolescentis, B. bifidum and B. longum.
In addition to supporting gut microbiota, the video explains how Bimuno® GOS promotes the production of short-chain fatty acids (SCFAs), such as acetate and butyrate, and reduces gut pH to support a healthier gut environment. These findings show that meaningful gut health benefits can be achieved at doses much lower than traditionally used, providing formulators with greater flexibility for compact capsules and tablets.
The research reinforces Bimuno GOS’s position as a clinically backed prebiotic that efficiently supports gut health and microbiome balance, making it a versatile ingredient for the health and nutrition industry